Aerovate Therapeutics (AVTE)
(Delayed Data from NSDQ)
$17.45 USD
-0.21 (-1.19%)
Updated May 31, 2024 04:00 PM ET
After-Market: $17.50 +0.05 (0.29%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Aerovate Therapeutics, Inc. [AVTE]
Reports for Purchase
Showing records 21 - 38 ( 38 total )
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Virtual NDR Highlights Ahead of Gossamer''s Ph2 TORREY Results for Seralutinib
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q3: Eyes on Upcoming Competitor Data Late Nov/Early Dec
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
IMPRESsing Upon Disease Modification in PAH; Assuming Coverage at OP & $27 PT
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2: MOA Comes into Focus Ahead of Competitor Data in November; PT to $32
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KOL Call Highlights: Insights into the PAH Commercial & Clinical Landscape
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1: Topline Ph2b Data Expected in Q4:23/Q1:24, Upcoming Competitor Catalysts
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY21: Focus Remains on Ongoing IMPAHCT Trial, Competitor Catalysts in 2022
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2b/3 IMPAHCT Underway; P2b Topline On-Track for Mid-23
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q3: Steady Progress Heading into Execution Year, Competitor Data in 2022
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Highlights from PAH Evolving Landscape KOL Call: Need for Novel Mechanisms
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2: IPO''d & Ready-to-Go; Executing Ahead of Value-Driving Catalyst in Mid-2023
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Aerosol-ving Disease Modification for PAH; Initiating at OUTPERFORM and $23 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L